Departments of Surgery, Academic Medical Center, the Netherlands.
Hepatology. 2014 Mar;59(3):996-1006. doi: 10.1002/hep.26781. Epub 2014 Jan 30.
Diagnosis of hepatocellular carcinoma (HCC) primarily involves imaging. The aim of this study was to assess the accuracy of (18) F-fluorocholine ((18) F-FCH) positron emission tomography (PET) for detection of HCC and evaluation of extent of disease. Patients with HCC >1 cm were included between 2009 and July 2011, and follow-up closed in February 2013. Diagnosis was based on American Association for the Study of Liver Diseases criteria, and all patients underwent (18) F-FCH PET/computed tomography (CT) at baseline before treatment, 6 underwent a second PET/CT posttreatment, and 1 a third during follow-up. Whole-body PET and low-dose CT imaging were performed 15 minutes after (18) F-FCH injection. Evaluation of imaging was done with standardized uptake value (SUV) ratios: SUV maximum of the lesion divided by the SUV mean of surrounding tissue. Statistical analyses included descriptive analyses, receiver operating characteristic curve, McNemar's test, and Kaplan-Meier's test at 5% level of significance. Twenty-nine patients revealed 53 intrahepatic lesions. In 48 of 53 lesions, (18) F-FCH PET was positive (SUVratio , 1.95 ± 0.66; sensitivity, 88%; specificity, 100%). PET/CT showed uptake in 18 extrahepatic lesions and no uptake in 3 lesions affirmed non-HCC lesions; all lesions were confirmed with additional investigation (accuracy, 100%). In 17 of 29 patients, additional lesions were found on PET/CT imaging, with implications for treatment in 15 patients. Posttreatment PET/CT showed identical results, compared with standard treatment evaluation.
This study shows additional value of (18) F-FCH PET/CT for patients with HCC. (18) F-FCH PET/CT has implications for staging, management, and treatment evaluation because of accurate assessment of extrahepatic disease.
肝细胞癌(HCC)的诊断主要涉及影像学检查。本研究旨在评估氟[18F]胆碱([18F-FCH)正电子发射断层扫描(PET)对 HCC 的检测和疾病程度评估的准确性。2009 年至 2011 年 7 月期间纳入 HCC >1cm 的患者,随访于 2013 年 2 月结束。诊断基于美国肝病研究协会标准,所有患者在治疗前均行[18F-FCH] PET/CT 检查,6 例患者在治疗后行第二次 PET/CT 检查,1 例患者在随访期间行第三次 PET/CT 检查。在[18F-FCH 注射后 15 分钟进行全身 PET 和低剂量 CT 成像。采用标准化摄取值(SUV)比值评估影像学表现:病变的 SUV 最大值除以周围组织的 SUV 平均值。统计分析包括描述性分析、受试者工作特征曲线、McNemar 检验和 5%显著性水平的 Kaplan-Meier 检验。29 例患者显示 53 个肝内病变。在 53 个病变中,48 个(18)F-FCH PET 阳性(SUV 比值为 1.95±0.66;敏感性为 88%;特异性为 100%)。PET/CT 显示 18 个肝外病变有摄取,3 个病变无摄取,证实为非 HCC 病变;所有病变均通过进一步检查证实(准确率为 100%)。在 29 例患者中有 17 例患者在 PET/CT 图像上发现了其他病变,其中 15 例患者的治疗方案受到影响。与标准治疗评估相比,治疗后 PET/CT 显示出相同的结果。
本研究表明氟[18F]胆碱([18F-FCH)PET/CT 对 HCC 患者具有额外的价值。由于对肝外疾病的准确评估,[18F-FCH] PET/CT 对分期、管理和治疗评估具有重要意义。